Predictors of non-responders after intravitreal ranibizumab therapy
| As judged by | BCVA | Fundus finding | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Crude | Multivariate, adjusted | Crude | Multivariate, adjusted | |||||||||
| p Value | OR | 95% CI | p Value | OR | 95% CI | p Value | OR | 95% CI | p Value | OR | 95% CI | |
| Age | 0.143 | 1.041 | 0.997 to 0.097 | – | – | – | 0.767 | 1.007 | 0.961 to 1.055 | – | – | – |
| Gender | 0.668 | 0.800 | 0.288 to 2.219 | – | – | 0.692 | 0.824 | 0.315 to 2.152 | – | – | – | |
| BCVA | 0.189 | 1.953 | 0.719 to 5.307 | 0.551 | 0.732 | 0.262 to 2.044 | 0.984 | 0.990 | 0.352 to 2.783 | 0.940 | 0.956 | 0.995 to 1.001 |
| AMD type | ||||||||||||
| PCV† | 0.191 | 1.932 | 0.719 to 5.191 | 0.154 | 2.125 | 0.755 to 5.983 | 0.134 | 0.443 | 0.153 to 1.284 | 0.083 | 0.374 | 0.123 to 1.138 |
| RAP† | 0.889 | 1.123 | 0.220 to 5.725 | 0.722 | 0.726 | 0.125 to 4.234 | –‡ | –‡ | –‡ | –‡ | –‡ | –‡ |
| CRT | 0.093 | 1.002 | 1.000 to 1.004 | – | – | – | 0.154 | 0.998 | 0.995 to 1.001 | – | – | – |
| GLD | 0.273 | 1.000 | 1.000 to 1.000 | – | – | – | 0.297 | 1.000 | 1.000 to 1.000 | – | – | – |
| Type 1 CNV | 0.191 | 2.378 | 0.648 to 8.723 | 0.141 | 2.741 | 0.717 to 10.479 | 0.026* | 5.500 | 1.221 to 24.771 | 0.017* | 6.462 | 1.390 to 30.036 |
| Fundus finding | ||||||||||||
| Serous PED | 0.007** | 5.937 | 1.623 to 21.722 | 0.039* | 4.123 | 1.077 to 15.782 | 0.355 | 1.946 | 0.477 to 7.946 | 0.335 | 2.156 | 0.453 to 10.266 |
| Haemorrhagic PED | 0.043* | 12.526 | 1.082 to 144.986 | 0.096 | 8.443 | 0.685 to 104.061 | –‡ | –‡ | –‡ | –‡ | –‡ | –‡ |
| Fibrovascular PED | 0.004** | 13.882 | 2.360 to 81.656 | 0.005** | 22.896 | 2.613 to 200.607 | 0.002** | 30.526 | 3.379 to 275.817 | 0.005** | 33.507 | 2.949 to 380.691 |
Serous PED>4 DD, haemorrhagic PED>4 DD, and fibrovascular PED>3 DD were included. In the multivariable analysis, potential risk factors for non-responders were adjusted respectively for age, gender, CRT and GLD at the time of initial intravitreal ranibizumab.
*p<0.05, **p<0.01.
†Reference typical AMD.
‡Unanalysable because all subjects were responders.
AMD, age-related macular degeneration; BCVA, best corrected visual acuity; CNV, choroidal neovascularisation; CRT, central retinal thickness; GLD, greatest linear dimension; PCV, polypoidal choroidal vasculopathy; PED, pigment epithelial detachment; RAP, retinal angiomatous proliferation.